Authors' recommendations: Acute myeloid leukaemia is a rare type of cancer that affects the way blood cells are developed so that they do not work properly. This leads to an increased risk of infection, as well as symptoms such as anaemia and bruising. It can affect people at any age but is more common in people over 65. Chemotherapy drugs can be very effective in the treatment of acute myeloid leukaemia. In some situations, these drugs are combined with stem cell or bone marrow transplant to improve the chances of curing the leukaemia. However, some patients cannot tolerate intensive chemotherapy and non-intensive treatments are offered. CPX-351 is a new product aimed at patients aged 60 years or older which delivers two of the most commonly used drugs in the treatment of acute myeloid leukaemia (cytarabine and daunorubicin) in a new combination. If CPX-351 is licensed for use in the UK, it could be a new treatment option for these patients. A current trial is looking to see whether CPX-351 can improve survival compared to an existing treatment, and whether it is safe to use.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/cpx-351-vyxeos-for-elderly-patients-with-newly-diagnosed-acute-myeloid-leukaemia-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)